115 related articles for article (PubMed ID: 24714773)
1. The role of relative lymphocyte count as a biomarker for the effect of catumaxomab on survival in malignant ascites patients: results from a phase II/III study.
Heiss MM; Ströhlein MA; Bokemeyer C; Arnold D; Parsons SL; Seimetz D; Lindhofer H; Schulze E; Hennig M
Clin Cancer Res; 2014 Jun; 20(12):3348-57. PubMed ID: 24714773
[TBL] [Abstract][Full Text] [Related]
2. Relative lymphocyte count is a prognostic parameter in cancer patients with catumaxomab immunotherapy.
Ströhlein MA; Lefering R; Bulian DR; Heiss MM
Med Hypotheses; 2014 Mar; 82(3):295-9. PubMed ID: 24411128
[TBL] [Abstract][Full Text] [Related]
3. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.
Heiss MM; Murawa P; Koralewski P; Kutarska E; Kolesnik OO; Ivanchenko VV; Dudnichenko AS; Aleknaviciene B; Razbadauskas A; Gore M; Ganea-Motan E; Ciuleanu T; Wimberger P; Schmittel A; Schmalfeldt B; Burges A; Bokemeyer C; Lindhofer H; Lahr A; Parsons SL
Int J Cancer; 2010 Nov; 127(9):2209-21. PubMed ID: 20473913
[TBL] [Abstract][Full Text] [Related]
4. Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone.
Wimberger P; Gilet H; Gonschior AK; Heiss MM; Moehler M; Oskay-Oezcelik G; Al-Batran SE; Schmalfeldt B; Schmittel A; Schulze E; Parsons SL
Ann Oncol; 2012 Aug; 23(8):1979-1985. PubMed ID: 22734013
[TBL] [Abstract][Full Text] [Related]
5. Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites.
Bokemeyer C
Expert Opin Biol Ther; 2010 Aug; 10(8):1259-69. PubMed ID: 20624115
[TBL] [Abstract][Full Text] [Related]
6. Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites.
Ott MG; Marmé F; Moldenhauer G; Lindhofer H; Hennig M; Spannagl R; Essing MM; Linke R; Seimetz D
Int J Cancer; 2012 May; 130(9):2195-203. PubMed ID: 21702044
[TBL] [Abstract][Full Text] [Related]
7. Catumaxomab: in malignant ascites.
Frampton JE
Drugs; 2012 Jul; 72(10):1399-410. PubMed ID: 22676343
[TBL] [Abstract][Full Text] [Related]
8. Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study.
Sehouli J; Pietzner K; Wimberger P; Vergote I; Rosenberg P; Schneeweiss A; Bokemeyer C; Salat C; Scambia G; Berton-Rigaud D; Santoro A; Cervantes A; Trédan O; Tournigand C; Colombo N; Dudnichenko AS; Westermann A; Friccius-Quecke H; Lordick F
Med Oncol; 2014 Aug; 31(8):76. PubMed ID: 24965536
[TBL] [Abstract][Full Text] [Related]
9. Outpatient Intraperitoneal Catumaxomab Therapy for Malignant Ascites Related to Advanced Gynecologic Neoplasms.
Kurbacher CM; Horn O; Kurbacher JA; Herz S; Kurbacher AT; Hildenbrand R; Bollmann R
Oncologist; 2015 Nov; 20(11):1333-41. PubMed ID: 26417039
[TBL] [Abstract][Full Text] [Related]
10. Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab.
Seeber A; Braicu I; Untergasser G; Nassir M; Fong D; Botta L; Gastl G; Fiegl H; Zeimet A; Sehouli J; Spizzo G
Oncotarget; 2015 Sep; 6(28):25017-23. PubMed ID: 26296970
[TBL] [Abstract][Full Text] [Related]
11. Dramatic Response to Catumaxomab Treatment for Malign Ascites Related to Renal Cell Carcinoma With Sarcomotoid Differentiation.
Pilanc KN; Ordu Ç; Akpnar H; Balc C; Başsülü N; Köksal Üİ; Elbüken F; Okutur K; Bülbül G; Sağlam S; Demir G
Am J Ther; 2016; 23(4):e1078-81. PubMed ID: 24732906
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal catumaxomab therapy in a cirrhotic patient with malignant ascites due to urethelial carcinoma: a case report.
Krawczyk M; Zimmermann S; Vidacek D; Lammert F
Onkologie; 2012; 35(10):592-4. PubMed ID: 23038231
[TBL] [Abstract][Full Text] [Related]
13. Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3).
Jäger M; Schoberth A; Ruf P; Hess J; Hennig M; Schmalfeldt B; Wimberger P; Ströhlein M; Theissen B; Heiss MM; Lindhofer H
Cancer Res; 2012 Jan; 72(1):24-32. PubMed ID: 22044753
[TBL] [Abstract][Full Text] [Related]
14. Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study.
Pietzner K; Vergote I; Santoro A; Chekerov R; Marmé F; Rosenberg P; Martinius H; Friccius-Quecke H; Sehouli J
Med Oncol; 2014 Dec; 31(12):308. PubMed ID: 25367854
[TBL] [Abstract][Full Text] [Related]
15. Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer.
Petrelli F; Borgonovo K; Lonati V; Elia S; Barni S
Target Oncol; 2013 Dec; 8(4):291-4. PubMed ID: 23197249
[TBL] [Abstract][Full Text] [Related]
16. Catumaxomab: malignant ascites: unjustified marketing authorisation.
Prescrire Int; 2010 Oct; 19(109):207-9. PubMed ID: 21180374
[TBL] [Abstract][Full Text] [Related]
17. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study.
Berek JS; Edwards RP; Parker LP; DeMars LR; Herzog TJ; Lentz SS; Morris RT; Akerley WL; Holloway RW; Method MW; Plaxe SC; Walker JL; Friccius-Quecke H; Krasner CN
Int J Gynecol Cancer; 2014 Nov; 24(9):1583-9. PubMed ID: 25254563
[TBL] [Abstract][Full Text] [Related]
18. The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis.
Ströhlein MA; Heiss MM
Future Oncol; 2010 Sep; 6(9):1387-94. PubMed ID: 20919824
[TBL] [Abstract][Full Text] [Related]
19. Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAM×anti-CD3).
Fossati M; Buzzonetti A; Monego G; Catzola V; Scambia G; Fattorossi A; Battaglia A
Gynecol Oncol; 2015 Aug; 138(2):343-51. PubMed ID: 26049121
[TBL] [Abstract][Full Text] [Related]
20. Treatment of malignant ascites with a second cycle of catumaxomab in gastric signet cell carcinoma--a report of 2 cases.
Thomaidis T; Wörns MA; Galle PR; Möhler M; Schattenberg JM
Oncol Res Treat; 2014; 37(11):674-7. PubMed ID: 25427585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
